NCT07011706 - ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

October 31, 2026

Conditions

Atopic DermatitisAtopicDermatitisADEczema

Interventions

DRUG

ATI-045

ATI-045 group

DRUG

Placebo

Placebo group

Trial Locations (24)

10023

RECRUITING

Aclaris Study Site, New York

10075

RECRUITING

Aclaris Study Site, New York

23502

ACTIVE_NOT_RECRUITING

Aclaris Study Site, Norfolk

27518

RECRUITING

Aclaris Clinical Site, Cary

33134

RECRUITING

Aclaris Study Site, Coral Gables

33162

RECRUITING

Aclaris Study Site, North Miami Beach

33172

RECRUITING

Aclaris Study Site, Sweetwater

33607

RECRUITING

Aclaris Study Site, Tampa

42104

RECRUITING

Aclaris Study Site, Bowling Green

46250

RECRUITING

Aclaris Study Site, Indianapolis

47129

RECRUITING

Aclaris Study Site, Clarksville

48326

RECRUITING

Aclaris Study Site, Auburn Hills

64506

RECRUITING

Aclaris Study Site, Saint Joseph

71913

RECRUITING

Aclaris Study Site, Bryant

78213

RECRUITING

Aclaris Study Site, San Antonio

78218

RECRUITING

Aclaris Study Site, San Antonio

90045

RECRUITING

Aclaris Study Site, Los Angeles

90404

RECRUITING

Aclaris Study Site, Santa Monica

92024

RECRUITING

Aclaris Study Site, Encinitas

92056

RECRUITING

Aclaris Study Site, Oceanside

L3P 1X3

RECRUITING

Aclaris Site, Markham

L4Y 4C5

RECRUITING

Aclaris Site, Mississauga

L4B 1A5

RECRUITING

Aclaris Site, Richmond Hill

M4W 2N2

RECRUITING

Aclaris Site, Toronto